The Use Of UHPLC In Post-Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Use Of UHPLC In Post-Drug Development
Ultra high performance liquid chromatography (UHPLC) offers increased performance compared with high performance liquid chromatography (HPLC), including shorter analysis times and increased sensitivity. These features offer many advantages in post-drug development, helping to reduce both the amount of solvent and sample required and, therefore, the associated costs.


Pharmaceutical Technology Europe
Volume 23, Issue 1

How have UHPLC systems advanced in recent years?

One of the key benefits of newer UHPLC systems is that they can offer combined HPLC/UHPLC operation without sacrificing performance. Although several combined HPLC/UHPLC systems have been available in the market for some time, their main drawback has been loss of performance when operating outside the specific set of conditions they have been optimised for.1 Another limitation has been the lack of quaternary capabilities. Such capabilities require low pressure mixing and in the past, low pressure mixing demanded larger delay (dwell) volumes for optimum performance, which is detrimental for true UHPLC operation to achieve optimum performance and allow proper solvent mixing.

With newly developed pump technology, however, this is no longer the case. This technology employs unique force sensors to modulate pumping efficiency based on assessed mobile phase compressibility; thereby enabling the delivery of accurate and reproducible gradients with extremely low delay volumes. The force sensors employed in these pumps measure the actual force that is needed to move each piston and can be used to determine compressibility of the displaced solvent in real-time. As such, variations in compressibility caused by changes in mobile phase composition and temperature, etc., can be accounted for and compensated during each individual piston stroke. The end result is volumetric, virtually pulsation free flow from the pump over its complete dynamic working range. The high stability of flow and pressure also eliminates the need for a pulse dampening device, which increases ease of use. Overall, the technology has helped increase the accuracy and reliability in pump performance under all operating conditions.

Some newly developed systems also offer quaternary mixing capabilities, which are extremely useful when developing chromatographic methods and when more than two solvents are needed to achieve adequate chromatographic resolution, such as when working with complex samples.

Sergio Guazzotti is Senior Global Product Marketing Manager, Liquid Chromatography at Thermo Fisher Scientific

Reference

1. Thermo Fisher, Application Note 405: Analysis of Simvastatin Tablets by High Speed LC (2007). http://www.thermo.com/appnotes


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here